Haemonetics Corp revenue
Haemonetics Corp's revenue was $1.33bn in fiscal 2026, down 2.0% on the year before. Since fiscal 2010 ($645m) it has grown at a compound 4.6% a year. Over the last twelve months it was $1.35bn.
Revenue history
| Fiscal year | 2010Apr 2010 | 2011Apr 2011 | 2012Mar 2012 | 2013Mar 2013 | 2014Mar 2014 | 2015Mar 2015 | 2016Apr 2016 | 2017Apr 2017 | 2018Mar 2018 | 2019Mar 2019 | 2020Mar 2020 | 2021Apr 2021 | 2022Apr 2022 | 2023Apr 2023 | 2024Mar 2024 | 2025Mar 2025 | 2026Mar 2026 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 645 | 677 | 728 | 892 | 939 | 910 | 909 | 886 | 904 | 968 | 988 | 870 | 993 | 1,169 | 1,309 | 1,361 | 1,334 | 1,352 |
| Growth on the year before | — | +4.8% | +7.6% | +22.6% | +5.2% | −3.0% | −0.2% | −2.5% | +2.0% | +7.0% | +2.2% | −11.9% | +14.1% | +17.7% | +12.0% | +4.0% | −2.0% | — |
| Gross profit | 337 | 355 | 369 | 428 | 468 | 434 | 406 | 378 | 412 | 418 | 485 | 398 | 506 | 615 | 692 | 749 | 788 | 798 |
| Gross margin | 52.3% | 52.5% | 50.7% | 48.0% | 49.9% | 47.7% | 44.7% | 42.7% | 45.6% | 43.2% | 49.0% | 45.7% | 50.9% | 52.6% | 52.8% | 55.0% | 59.0% | 59.0% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Hospital | $588M | 44.1% | ▲ 4.3% |
| Plasma | $524M | 39.3% | ▼ 2.0% |
| Blood Center | $221M | 16.6% | ▼ 15.3% |
| Line of business | Revenue | YoY |
|---|---|---|
| Hospital Products and Services | $588M | ▲ 4.3% |
| Blood Center Products and Services | $221M | ▼ 15.3% |
These categories overlap or exclude eliminations, so shares aren't shown.
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $982M | 73.6% | ▼ 2.8% |
| Europe | $185M | 13.9% | ▲ 5.3% |
| Asia | $87.2M | 6.5% | ▼ 5.5% |
| Japan | $68.2M | 5.1% | ▲ 9.3% |
| Other Countryor Region | $11.4M | 0.9% | ▼ 41.5% |
From Haemonetics Corp's 10-K filed May 20, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Haemonetics Corp | $1.35bn | 0.4% | 3.5% |
| Stevanato Group S.p.a. | $1.34bn | 12.3% | — |
| Penumbra Inc | $1.56bn | 17.0% | 16.2% |
| Merit Medical Systems Inc | $1.61bn | 9.1% | 9.5% |
| Integra Lifesciences Holdings Corp | $1.66bn | 0.8% | 2.4% |
| Tandem Diabetes Care Inc | $1.04bn | 4.0% | 9.6% |
Compare with peers
- Stevanato Group S.p.a. revenue
- Penumbra Inc revenue
- Merit Medical Systems Inc revenue
- Integra Lifesciences Holdings Corp revenue
- Tandem Diabetes Care Inc revenue
Head to head: HAE vs STVNHAE vs PENHAE vs MMSI
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies